Resultado de búsqueda
Hace 2 horas · Merck & Co. agreed to buy drug developer Eyebiotech Ltd. for as much as $3 billion, scooping up the UK biotech as it prepares for increasing price pressure on Keytruda, its top-selling cancer ...
Hace 2 horas · At MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines.
Hace 13 horas · Merck & Co. is focusing in on eye diseases with the $3 billion acquisition of ophthalmology-focused Eyebiotech. The deal features $1.3 billion in cash up front and $1.7 billion in potential ...
Hace 13 horas · Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK)of its portfolio company EyeBio for a potential value of $3 billion This acquisition reflects the significant clinical progress ...
Hace 5 horas · Merck nears a $1.3B deal to acquire Eyebiotech, a clinical-stage ophthalmology biotech, as it expands into the growing eye-care market.
Hace 13 horas · Merck & Co., Inc. MRK is reportedly on the verge of acquiring EyeBio, an eye drug company, for a sum of $1.3 billion.This acquisition is expected to significantly expand Merck’s presence in the ...
Hace 8 horas · London: Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company Eyebiotech in an agreement that could see an additional $1.7 billion in milestone payments, ...
